Thrasos Therapeutics, a Montreal, QC, Canada-based clinical stage, biotherapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease, has completed a $35m financing.
The company intends to use the capital for the development of THR-184, its lead product candidate for the treatment of acute kidney injury (AKI), through Phase 2 clinical proof of concept.
The round was led by new backer SR One, with funds coming from the GSK Canada Life Sciences Innovation Fund, with participation from:
– new investors: Advanced Technology Ventures (ATV), Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures; as well as
– existing investor: SW Co.
Thrasos is led by President and CEO Richard Andrews.